- Oops!Something went wrong.Please try again later.
Denali Therapeutics Inc. DNLI was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 60.2% in the past one-month time frame.
The company has seen four negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Denali Therapeutics currently has a Zacks Rank #5 (Strong Sell) while its Earnings ESP is negative.
Denali Therapeutics Inc. Price
Denali Therapeutics Inc. price | Denali Therapeutics Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Abeona Therapeutics Inc. ABEO, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abeona Therapeutics Inc. (ABEO) : Free Stock Analysis Report
Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research